Quabodepistat
Quabodepistat combo shows promise for safer, faster tuberculosis treatment
Approximately 1.3 million fatalities occurred due to tuberculosis in 2022.
Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or both, offering potential for shorter and more tolerable tuberculosis treatment regimens.
Cutting-edge tuberculosis therapy: Researchers test quabodepistat combinations, aiming for shorter, safer treatments to combat drug resistance and improve patient outcomes.
Currently, standard treatment of pulmonary tuberculosis involves inhibiting bacilli replication, eliminating dormant bacilli, and preventing drug resistance. Furthermore, patients with drug-susceptible pulmonary disease are treated with a six-month course of rifampicin, isoniazid, ethambutol, and pyrazinamide.
Healthy adults exhibited tolerance to quabodepistat at doses between 10 mg and 480 mg. The first stage of an early bactericidal activity study identified that a daily dose of 30 mg could be an optimal dose for further assessment in the second stage of the EBA study. A pilot study was also conducted to evaluate the pharmacokinetics and bactericidal activity of quabodepistat when combined with delamanid and bedaquiline on days one and 14 of the trial.
Previous in vitro and in vivo studies have highlighted the high bactericidal activity of quabodepistat with low minimum inhibitory concentrations in the laboratory and clinically isolated tuberculosis strains. Quabodepistat is a 3,4-dihydrocarbostyril derivative that can inhibit ecaprenylphosphorylβ-D-ribose 2´-oxidase, a vital enzyme for Mycobacterium tuberculosis cell-wall biosynthesis.
Healthy adults exhibited tolerance to quabodepistat at doses between 10 mg and 480 mg. The first stage of an early bactericidal activity (EBA) study identified that a daily dose of 30 mg could be an optimal dose for further assessment in the second stage of the EBA study.
The current study reports the second stage of the EBA study, which is an open-label, randomized, active-controlled, and parallel-group study conducted in two research sites in South Africa.
